The preclinical natural history of serous ovarian cancer: defining the target for early detection
about
Mathematical model identifies blood biomarker-based early cancer detection strategies and limitationsOvarian cancer screening--current status, future directionsSociety of Gynecologic Oncology recommendations for the prevention of ovarian cancerThe tumor as an organ: comprehensive spatial and temporal modeling of the tumor and its microenvironmentGenome-scale screen for DNA methylation-based detection markers for ovarian cancerRationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the EvidenceResearch Needs for Understanding the Biology of Overdiagnosis in Cancer Screening.Design and characterization of a combined OCT and wide field imaging falloposcope for ovarian cancer detectionDNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines.Assessing lead time of selected ovarian cancer biomarkers: a nested case-control studyRetooling the pap smear for ovarian and endometrial cancer detection.Ultrasound Monitoring of Extant Adnexal Masses in the Era of Type 1 and Type 2 Ovarian Cancers: Lessons Learned From Ovarian Cancer Screening Trials.Integrative proteomic analysis of serum and peritoneal fluids helps identify proteins that are up-regulated in serum of women with ovarian cancerESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinoma.Ovarian cancer development and metastasis.Comparing the benefits of screening for breast cancer and lung cancer using a novel natural history model.Analysis of serial ovarian volume measurements and incidence of ovarian cancer: implications for pathogenesis.Development of serous ovarian cancer is associated with the expression of homologous recombination pathway proteins.Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.New views on the pathogenesis of high-grade pelvic serous carcinoma with suggestions for advancing future researchRisk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS).fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma.Comparative Study of Alterations in Tri-iodothyronine (T3) and Thyroxine (T4) Hormone Levels in Breast and Ovarian Cancer.On the path to translation: Highlights from the 2010 Canadian Conference on Ovarian Cancer Research.Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms.Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patientsTranslational genomics: the challenge of developing cancer biomarkers.Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytesModeling the Dynamics of High-Grade Serous Ovarian Cancer Progression for Transvaginal Ultrasound-Based Screening and Early DetectionRethinking ovarian cancer: recommendations for improving outcomes.Highly sensitive detection of cancer cells using femtosecond dual-wavelength near-IR two-photon imaging.Determination of reference intervals of serum levels of human epididymis protein 4 (HE4) in Chinese womenA branching process model of ovarian cancer.Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study.Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening scheduleProphylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers.Global ovarian cancer health disparities.The peritoneal tumour microenvironment of high-grade serous ovarian cancer.Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.
P2860
Q24614865-BEBEC45C-7D51-417A-A6AF-94331151C646Q27004471-571D00D4-4EA6-4D33-8DD6-8128AFBF1A7DQ27009306-BF5C141D-D894-4CDE-8348-04DE6BAF8704Q27318697-A6035F43-608F-402D-B840-3CFF9589788CQ28741759-AFE27F85-F7D4-4F9D-9266-819294580C4BQ30250107-01E0CD54-C2FE-4DD6-8116-2D2A77D19C5BQ30252065-6F8A3E74-EEE4-4F29-BD10-24E66BA294D7Q30834795-9C585990-CDD4-4FCF-81F6-088012624781Q33533746-7EFB42FE-EFC3-4030-A5B6-76D4D6C68412Q33574039-937FC246-426D-44C4-91C7-A5CDAA3711DAQ33829230-3669ADDA-6464-4F89-B1E5-CC20CE0F9EF6Q33850475-FF0393DE-A07E-4868-A561-5F3BCEF9B475Q33915144-DBFE5217-B008-4D21-A42D-A52FC683B10EQ34031167-697CB282-5878-44DC-9797-309B115C4800Q34086819-6D568CC2-6432-41A4-8563-DC60A2951A0BQ34097395-538AC701-6BF8-4F08-A8AB-4BF83637A6F8Q34209092-DFB1210E-5A53-4294-AC11-E05B10E07A0EQ34253229-E7B58725-A3A3-44D0-B995-A7A87E050468Q34308808-64E46355-C5D4-48C1-95D8-CE66A00CA59FQ34543315-BF3C32F8-B936-499C-A445-80F0EC13BB96Q34641672-74A4784A-22E4-428E-BAD8-CB3A7A28782DQ35021181-9D905635-B72E-46B9-86C4-BBF666A42884Q35061028-FB20DDA7-CAEA-402D-AED0-54550AB31B6AQ35111420-848CFA29-93DD-46E7-8F2C-5F6D4F95FFC7Q35166076-6B5AB1ED-AAAC-4C3C-BE2E-0B48EB86004DQ35177861-281F03E0-4080-4D92-A909-3FD196B78EBBQ35694362-B41AB4F2-0C60-4C4C-B860-FCFF5AA04A63Q35721991-9B437606-BA71-40D0-A1AE-ADC0FC6A6507Q35847903-13D6E462-E264-45E6-8808-C6490F1D85E4Q36039369-B30F7896-D09E-45B7-B9D0-36CE57FAABE8Q36050883-E4ED3B4B-EAC7-40E3-9A78-44605A39EDF4Q36091467-640E9F72-5CD4-4F7C-AFC7-A0A1F0E6DE0BQ36262845-1CE3A00F-1498-4A1D-BBA8-DE051FFE522AQ36339013-06E5470D-3486-4D9A-B922-09C15C4E52C0Q36369334-C90A9133-75D3-4BDF-9E71-9BF41E01A66BQ36490048-28681D0F-BB9C-43F0-A6A7-4B7E38C8DDA9Q36634141-E00FC720-7ECC-4B91-B65C-4519F022C6C9Q36718113-7F15986F-40C8-4B26-A2FA-EE0591F92E10Q36719074-F4A03925-94D9-4F82-A66F-81646428AB14Q36738628-A531E63D-449E-430D-AAB2-8287F6A97054
P2860
The preclinical natural history of serous ovarian cancer: defining the target for early detection
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The preclinical natural histor ...... the target for early detection
@ast
The preclinical natural histor ...... the target for early detection
@en
type
label
The preclinical natural histor ...... the target for early detection
@ast
The preclinical natural histor ...... the target for early detection
@en
prefLabel
The preclinical natural histor ...... the target for early detection
@ast
The preclinical natural histor ...... the target for early detection
@en
P2860
P1433
P1476
The preclinical natural histor ...... the target for early detection
@en
P2093
Chana Palmer
P2860
P304
P356
10.1371/JOURNAL.PMED.1000114
P407
P577
2009-07-28T00:00:00Z